Crc October 2019

crc@lists.oulu.fi

15 participants
53 discussions

Reminder tomorrow: Are structural brain changes in Schizophrenia related to antipsychotic medication? – insights from pre-clinical studies - Kontinkangas campus research talk by Dr. Anthony Vernon
by Mirja Peltola 16 Oct '19

16 Oct '19

Reminder Tomorrow Kontinkangas Campus Seminar Series<https://www.oulu.fi/uniogs/dp/hbsdp/guest-seminars> Dear all, On 17th of October 14:00–15:30 in Lecture hall of Dentistry (H1091) Dr. Anthony Vernon from London, UK, will give a lecture with a title: Are structural brain changes in Schizophrenia related to antipsychotic medication? – insights from pre-clinical studies Short introduction: Dr. Anthony Vernon is a researcher and research group leader in Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, London, United Kingdom https://kclpure.kcl.ac.uk/portal/en/persons/anthony-vernon(9bc872c8-e1b5-4a… Anthony Vernon’s lab is an inter-disciplinary research group working at the interface of fundamental neuroscience and clinical research into mental health. Current work in the laboratory is focused on two themes: 1. Understanding the effects of psychotropic drugs used in the treatment of mental health problems, such as antipsychotics and antidepressants, on the nervous, immune and endocrine systems. 2. To understand how alterations in brain structure and function observed in patients with mental health disorders align with appropriate experimental models. A common thread linking both themes is the role of glial cells and immune dysfunction as both a pathological mechanism and putative treatment target for mental illness. Specifically, Vernon’s group is interested in the role of neuron-microglia interactions in the pathophysiology of psychiatric disorders and whether glial cells play a role in the therapeutic and adverse effects of antipsychotic and antidepressant drugs. Anthony Vernon’s lab primarily study rodent models, but also human induced pluripotent stem cells (hIPSC) differentiated towards neural and glial cell fates. They use a broad range of methods that include, but are not limited to, small animal magnetic resonance imaging (MRI; clinically comparable technology), next generation 3D histopathology (CLARITY), conventional 2D neuropathology, biochemistry, proteomics and transcriptomics. Anthony Vernon’s research is important to advance knowledge of causative biological pathways and mechanisms to provide much-needed and more effective therapies for mental health problems, for example schizophrenia. Regarding 25th April lecture, understanding the long-term impact of antipsychotic drug treatment will inform the clinical use of these drugs and improve risk:benefit profiles and potentially response rates. Highlighted publications: Vernon et al., Biol. Psychiatry, 2014, DOI:10.1016/j.biopsych.2013.09.012<https://doi.org/10.1016/j.biopsych.2013.09.012> Cotel et al., Eur. NPP, 2015, DOI:10.1016/j.euroneuro.2015.08.004<https://doi.org/10.1016/j.euroneuro.2015.08.004> Crum et al., Psych. Med., 2016, DOI:10.1017/S0033291716001768<https://doi.org/10.1017/S0033291716001768> Hawkins et al., Human Brain Mapping, 2018, DOI:10.1002/hbm.23844<https://doi.org/10.1002/hbm.23844> Coffee and snacks will be served before the seminar in the lecture hall! PhD Students’ credits: Attendance to 10 seminars -> 0,5 ECTS You are warmly welcome! Feel free to distribute this announcement further! Best wishes, Mirja ------------------------------------------------------------------------------------------------------ Mirja Peltola Koordinaattori | Coordinator Oulun yliopisto | University of Oulu Terveys- ja biotieteiden tohtoriohjelma | Health and Biosciences Doctoral Programme Tel. 0294 48 5447 PO Box 5000, FI-90014 OULUN YLIOPISTO (Aapistie 5A, Room 474B) www.oulu.fi<http://www.oulu.fi/yliopisto> [cid:image001.jpg@01D58418.DDB1DB80] Follow us on Facebook<https://www.facebook.com/unioulu/>, Instagram<https://www.instagram.com/unioulu/?hl=fi>, Linkedin<https://www.linkedin.com/school/university-of-oulu/> and Twitter<https://twitter.com/unioulu>.

1 0

CRC:n pääovet / CRC main doors
by Antti Haapalainen 16 Oct '19

16 Oct '19

Hei, Kaikki elektronisella lukolla varustetut ovet, joiden kautta pääsee CRC:n tiloihin, menevät lukkoon 1.11. alkaen, ja ovat lukittuina 24/7. Hi, All the doors with electronic locks, which allow access to CRC facilities, are locked 24/7 as of 1st of November. Terv. Antti Haapalainen

1 0

FW: Fibrosis research video in YouTube
by Antti Haapalainen 16 Oct '19

16 Oct '19

From: Pirkko Huhtala <pirkko.huhtala(a)oulu.fi> Sent: 16. lokakuutata 2019 9:24 To: bco(a)lists.oulu.fi; fbmm(a)lists.oulu.fi; ltk-all <ltk-all(a)oulu.fi> Subject: Fibrosis research video in YouTube Dear all, a video about Fibrosis research in Oulu has been published in UniOulu YouTube channel. The video was prepared to introduce the Profi 3 tenure track professors and associate professors. Here is the direct link to the video: https://www.youtube.com/watch?v=5ufU71hoG-w (you may freely distribute). Kind regards Pirkko Huhtala Pirkko Huhtala, Ph.D. Coordinator Biocenter Oulu University of Oulu Mailing address: P.O.Box 5000, FIN-90014 University of Oulu Finland Street address: 476B, Aapistie 5A, FIN-90220 Oulu Tel. sis/int. 486101, ulk./Ext. 0294 486101 Tel. +358-294 486101 e-mail pirkko.huhtala(a)oulu.fi<mailto:pirkko.huhtala@oulu.fi> www.oulu.fi/biocenter<http://www.oulu.fi/biocenter>

1 0

Solulaskuri ThermoFisheriltä / Cell counter from ThermoFisher
by Antti Haapalainen 14 Oct '19

14 Oct '19

Hei, Saamme nyt testikäyttöön solulaskurin ThermoFisheriltä. Kyseessä on Countess II Automated Cell Counter. Laite saapuu tänään noin klo 15, jolloin samalla on mahdollista saada pikainen käyttökoulutus. Voin myös demota tämän laitteen käytön keskiviikkona klo 9 aikoihin CRC:n taukohuoneessa. Hi, We will now have a cell counter from ThermoFisher for test use. This is the Countess II Automated Cell Counter. The device will arrive today at approximately 3 pm. At the same time there is a chance to have a quick user training. I could, however, demo this device on Wednesday at 9 in the CRC coffee room. Terv. Antti

1 1

Opettaja, tutkija, opiskelija: Ota tekijänoikeudet haltuun! Koulutus 14.11.
by Maarit Jokela 14 Oct '19

14 Oct '19

[cid:image001.jpg@01D58275.20D98B10] Tervetuloa tekijänoikeuskoulutukseen 14.11.2019! Ilmoittaudu mukaan osoitteessa: http://bit.ly/Tekijanoikeuskoulutus2019 t. Maarit Maarit Jokela, PhD (Biochem.) Innovation Manager University of Oulu University Innovation Centre P.O.Box 4300 (street address: Erkki Koiso-Kanttilan katu 1) FI-90014 University of Oulu FINLAND tel. +358-40-355 9660 Internal mail: 8 INNO Room: YT104 / Linnanmaa campus https://fi.linkedin.com/in/maaritjokela [cid:image002.jpg@01D58275.20D98B10] Follow us on Facebook<https://www.facebook.com/unioulu/>, Instagram<https://www.instagram.com/unioulu/?hl=fi>, Linkedin<https://www.linkedin.com/school/university-of-oulu/> and Twitter<https://twitter.com/unioulu>. The content of this message is confidential. If you are not a recipient indicated or intended in this message or you think this message may have been addressed to you in error, please inform us by an email reply and then delete the message. In such case it is forbidden to copy, forward, or in any way reveal the contents of this message to anyone

1 0

MITOLINK seminar, Nov 5, Kontinkangas Campus
by Mirja Peltola 14 Oct '19

14 Oct '19

FYI MITOLINK Public seminar<https://www.oulu.fi/sites/default/files/content/Mitolink%20Minisymposium%20…> Programme in PDF >><https://www.oulu.fi/sites/default/files/content/Mitolink%20Minisymposium%20…> 5.11.2019, at 13:15, in H1091 (Dentistry) Speakers: 13:20 - 13:30 Anni Laari (Nordic Biosite): Sponsor presentation, Coffee and Pulla 13:30 - 13:50 Henna Tyynismaa (Stem Cells and Metabolism Research Program, University of Helsinki): "Tissue-specific effects of mitochondrial import proteostasis" 13:50 - 14:10 Sjoerd Wanrooij (Department of Medical Biochemistry and Biophysics, Umeå University): "The Role of G-quadruplexes in human mitochondrial DNA" 14:10 - 14:30 Eija Pirinen (ResearchProgram for Clinical and Molecular Metabolism, University of Helsinki): "Vitamin B3 as a booster of mitochondrial metabolism in humans" 14:30 - 14:50 Riikka Martikainen (A.I. Virtanen Institute for Molecular Science; University of Eastern Finland, Kuopio): "Defective mtDNA replication can challenge nuclear genome maintenance" Organizers: Reetta Hinttala (Faculty of Medicine, BCO) and Alexander Kastaniotis (FBMM), University of Oulu, for https://www.helsinki.fi/en/researchgroups/medical-neurogenetics-group/mitol… Supported by the Health and Biosciences Doctoral Programme of the University of Oulu Field specific credits can be earned according to UniOGS recommendations (attending to 10 scientific seminars: 0,5ECTS) (https://www.oulu.fi/uniogs/recommendations_of_ects) Feel free to distribute this announcement further. Best wishes, Mirja ------------------------------------------------------------------------------------------------------ Mirja Peltola Koordinaattori | Coordinator Oulun yliopisto | University of Oulu Terveys- ja biotieteiden tohtoriohjelma | Health and Biosciences Doctoral Programme Tel. 0294 48 5447 PO Box 5000, FI-90014 OULUN YLIOPISTO (Aapistie 5A, Room 474B) www.oulu.fi<http://www.oulu.fi/yliopisto> [cid:image001.jpg@01D5826C.3A99BB50] Follow us on Facebook<https://www.facebook.com/unioulu/>, Instagram<https://www.instagram.com/unioulu/?hl=fi>, Linkedin<https://www.linkedin.com/school/university-of-oulu/> and Twitter<https://twitter.com/unioulu>.

1 0

Reminder this Thursday: Are structural brain changes in Schizophrenia related to antipsychotic medication? – insights from pre-clinical studies - Kontinkangas campus research talk by Dr. Anthony Vernon
by Mirja Peltola 14 Oct '19

14 Oct '19

Reminder Kontinkangas Campus Seminar Series<https://www.oulu.fi/uniogs/dp/hbsdp/guest-seminars> Dear all, On 17th of October 14:00–15:30 in Lecture hall of Dentistry (H1091) Dr. Anthony Vernon from London, UK, will give a lecture with a title: Are structural brain changes in Schizophrenia related to antipsychotic medication? – insights from pre-clinical studies Short introduction: Dr. Anthony Vernon is a researcher and research group leader in Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, London, United Kingdom https://kclpure.kcl.ac.uk/portal/en/persons/anthony-vernon(9bc872c8-e1b5-4a… Anthony Vernon’s lab is an inter-disciplinary research group working at the interface of fundamental neuroscience and clinical research into mental health. Current work in the laboratory is focused on two themes: 1. Understanding the effects of psychotropic drugs used in the treatment of mental health problems, such as antipsychotics and antidepressants, on the nervous, immune and endocrine systems. 2. To understand how alterations in brain structure and function observed in patients with mental health disorders align with appropriate experimental models. A common thread linking both themes is the role of glial cells and immune dysfunction as both a pathological mechanism and putative treatment target for mental illness. Specifically, Vernon’s group is interested in the role of neuron-microglia interactions in the pathophysiology of psychiatric disorders and whether glial cells play a role in the therapeutic and adverse effects of antipsychotic and antidepressant drugs. Anthony Vernon’s lab primarily study rodent models, but also human induced pluripotent stem cells (hIPSC) differentiated towards neural and glial cell fates. They use a broad range of methods that include, but are not limited to, small animal magnetic resonance imaging (MRI; clinically comparable technology), next generation 3D histopathology (CLARITY), conventional 2D neuropathology, biochemistry, proteomics and transcriptomics. Anthony Vernon’s research is important to advance knowledge of causative biological pathways and mechanisms to provide much-needed and more effective therapies for mental health problems, for example schizophrenia. Regarding 25th April lecture, understanding the long-term impact of antipsychotic drug treatment will inform the clinical use of these drugs and improve risk:benefit profiles and potentially response rates. Highlighted publications: Vernon et al., Biol. Psychiatry, 2014, DOI:10.1016/j.biopsych.2013.09.012<https://doi.org/10.1016/j.biopsych.2013.09.012> Cotel et al., Eur. NPP, 2015, DOI:10.1016/j.euroneuro.2015.08.004<https://doi.org/10.1016/j.euroneuro.2015.08.004> Crum et al., Psych. Med., 2016, DOI:10.1017/S0033291716001768<https://doi.org/10.1017/S0033291716001768> Hawkins et al., Human Brain Mapping, 2018, DOI:10.1002/hbm.23844<https://doi.org/10.1002/hbm.23844> Coffee and snacks will be served before the seminar in the lecture hall! PhD Students’ credits: Attendance to 10 seminars -> 0,5 ECTS You are warmly welcome! Feel free to distribute this announcement further! Best wishes, Mirja ------------------------------------------------------------------------------------------------------ Mirja Peltola Koordinaattori | Coordinator Oulun yliopisto | University of Oulu Terveys- ja biotieteiden tohtoriohjelma | Health and Biosciences Doctoral Programme Tel. 0294 48 5447 PO Box 5000, FI-90014 OULUN YLIOPISTO (Aapistie 5A, Room 474B) www.oulu.fi<http://www.oulu.fi/yliopisto> [cid:image001.jpg@01D5826C.1EAD4B50] Follow us on Facebook<https://www.facebook.com/unioulu/>, Instagram<https://www.instagram.com/unioulu/?hl=fi>, Linkedin<https://www.linkedin.com/school/university-of-oulu/> and Twitter<https://twitter.com/unioulu>.

1 0

3D bioprinting seminar and demo
by Veli-Pekka Ronkainen 11 Oct '19

11 Oct '19

Dear all, Immuno Diagnostic is arranging one day 3D bioprinting seminar and demo on Tue Oct 29th, please find the invitation as an attachment. Regards, Veli-Pekka Ronkainen BCO LM Core

1 0

MRC Oulu News - October 11 - Public defences of dissertations
by Katja Riipinen 10 Oct '19

10 Oct '19

MRC Oulu News Hello everyone, Tomorrow, Friday October 11, there will be the following public defences of dissertations: Metformin, statins and the risk and prognosis of endometrial cancer in women with type 2 diabetes<https://www.oulu.fi/yliopisto/node/63912> Doctoral candidate: Licentiate of Medicine Reetta Arima Date: 11 October 2019, starting at 12.00 Location: Auditorium 4, Oulu University Hospital Opponent: Docent Sakari Hietanen, Turku University Hospital and University of Turku Custos: Professor Ulla Puistola, Oulu University Hospital and University of Oulu More about the thesis: http://jultika.oulu.fi/Record/isbn978-952-62-2346-9 Associations of low HDL cholesterol level and premature coronary heart disease with functionality and phospholipid composition of HDL and with plasma oxLDL antibody levels<http://jultika.oulu.fi/Record/isbn978-952-62-2336-0> Doctoral candidate: Licentiate of Medicine Timo Paavola Date: 11 October 2019, starting at 12.00 Location: Leena Palotie Auditorium 101A, the Faculty of Medicine, University of Oulu (Aapistie 5A) Opponent: Professor Elina Ikonen, University of Helsinki Custos: Docent Tuire Salonurmi, University of Oulu More about the thesis: http://jultika.oulu.fi/Record/isbn978-952-62-2336-0 BR, Katja --------------------------------------------------------------- Katja Riipinen, PhD, BHSc Koordinaattori | Coordinator Medical Research Center Oulu<https://www.oulu.fi/mrc/> | MRC Oulu Tel. 0294 48 5909, Mobile +358 50 472 9414 PO Box 5000, FI-90014 OULUN YLIOPISTO (Aapistie 5A, Room 347B) www.oulu.fi<http://www.oulu.fi/yliopisto> [cid:image001.jpg@01D57F54.8E3B9EB0][cid:image002.png@01D57F54.8E3B9EB0]

1 0

Innovative Medicines Initiatives programme draft, commenting open
by Emma Pirilä 09 Oct '19

09 Oct '19

Dear researchers, Please find attached a draft of the 2020 programme for Innovative Medicines Initiative. The main topics are these and they are presented in more detail in the attached pdf. The programme is open for commenting so if you are interested in the topics and wish to make an input to the programme, please just send me your comments (no later than 28.10) and I will forward them collectively and anonymously. IMI-calls are partly funded by the EU and partly by health tech/med tech/pharma companies and are open to consortia with a minimum of 3 organizations from 3 different EU-countries. With best regards, Emma IMI2 Call 20 topics are: - Topic 1: Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in Psoriatic Arthritis - Topic 2: Innovations to accelerate vaccine development and manufacture - Topic 3: Real-world clinical implementation of liquid biopsy - Topic 4: Tumour plasticity - Topic 5: Proton versus photon therapy for oesophageal cancer – a trimodality strategy - Topic 6: Handling of protein drug products and stability concerns - Topic 7: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)

1 0

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

Crc October 2019